Latest Insider Transactions at Ultragenyx Pharmaceutical Inc. (RARE)
This section provides a real-time view of insider transactions for Ultragenyx Pharmaceutical Inc. (RARE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Ultragenyx Pharmaceutical Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Ultragenyx Pharmaceutical Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 06
2021
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
307
-1.12%
|
$34,691
$113.68 P/Share
|
|
May 06
2021
|
Emil D Kakkis President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
852
-0.14%
|
$97,980
$115.71 P/Share
|
|
May 06
2021
|
Thomas Richard Kassberg CBO & EVP |
SELL
Open market or private sale
|
Direct |
363
-0.34%
|
$41,019
$113.69 P/Share
|
|
May 06
2021
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
142
-0.94%
|
$16,046
$113.67 P/Share
|
|
May 06
2021
|
John Richard Pinion |
SELL
Open market or private sale
|
Direct |
363
-0.72%
|
$41,019
$113.69 P/Share
|
|
May 06
2021
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
313
-1.03%
|
$35,369
$113.67 P/Share
|
|
May 06
2021
|
Dennis Karl Huang |
SELL
Open market or private sale
|
Direct |
363
-0.89%
|
$41,019
$113.68 P/Share
|
|
May 03
2021
|
Emil D Kakkis President & CEO |
SELL
Open market or private sale
|
Indirect |
30,000
-1.31%
|
$3,210,000
$107.8 P/Share
|
|
Apr 20
2021
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
396
-1.42%
|
$41,184
$104.28 P/Share
|
|
Apr 16
2021
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,500
+9.07%
|
-
|
|
Apr 15
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-11.33%
|
$545,000
$109.09 P/Share
|
|
Apr 15
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+10.18%
|
$275,000
$55.0 P/Share
|
|
Mar 08
2021
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,000
-18.13%
|
$360,000
$120.69 P/Share
|
|
Mar 02
2021
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
707
-2.48%
|
$97,566
$138.16 P/Share
|
|
Mar 01
2021
|
Emil D Kakkis President & CEO |
SELL
Open market or private sale
|
Indirect |
30,000
-1.29%
|
$4,230,000
$141.8 P/Share
|
|
Mar 01
2021
|
Emil D Kakkis President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,342
-2.67%
|
$2,320,564
$142.47 P/Share
|
|
Mar 01
2021
|
Emil D Kakkis President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
33,453
+2.69%
|
-
|
|
Mar 01
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,543
-10.4%
|
$626,934
$138.18 P/Share
|
|
Mar 01
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,136
+10.97%
|
-
|
|
Mar 01
2021
|
Mardi Dier CFO & Executive Vice President |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+10.78%
|
-
|
|
Mar 01
2021
|
Dennis Karl Huang |
SELL
Open market or private sale
|
Direct |
4,255
-9.45%
|
$587,190
$138.18 P/Share
|
|
Mar 01
2021
|
Dennis Karl Huang |
BUY
Grant, award, or other acquisition
|
Direct |
10,136
+10.7%
|
-
|
|
Mar 01
2021
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,470
-7.97%
|
$340,860
$138.17 P/Share
|
|
Mar 01
2021
|
Erik Harris EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,136
+15.14%
|
-
|
|
Mar 01
2021
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
732
-4.24%
|
$101,016
$138.17 P/Share
|
|
Mar 01
2021
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,560
+8.28%
|
-
|
|
Mar 01
2021
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,970
-11.61%
|
$547,860
$138.17 P/Share
|
|
Mar 01
2021
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,136
+13.81%
|
-
|
|
Mar 01
2021
|
John Richard Pinion |
SELL
Open market or private sale
|
Direct |
6,198
-10.98%
|
$855,324
$138.17 P/Share
|
|
Mar 01
2021
|
John Richard Pinion |
BUY
Grant, award, or other acquisition
|
Direct |
10,136
+8.6%
|
-
|
|
Mar 01
2021
|
Thomas Richard Kassberg CBO & EVP |
SELL
Open market or private sale
|
Direct |
4,572
-4.09%
|
$630,936
$138.17 P/Share
|
|
Mar 01
2021
|
Thomas Richard Kassberg CBO & EVP |
BUY
Grant, award, or other acquisition
|
Direct |
10,136
+4.44%
|
-
|
|
Feb 23
2021
|
William Aliski Director |
SELL
Bona fide gift
|
Direct |
1,000
-1.52%
|
-
|
|
Feb 19
2021
|
William Aliski Director |
SELL
Open market or private sale
|
Direct |
7,500
-10.25%
|
$1,117,500
$149.01 P/Share
|
|
Feb 19
2021
|
William Aliski Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+9.29%
|
$727,500
$97.85 P/Share
|
|
Jan 30
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,243
-6.27%
|
$314,020
$140.36 P/Share
|
|
Jan 15
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
25,000
-41.13%
|
$3,475,000
$139.18 P/Share
|
|
Jan 15
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+29.14%
|
$1,375,000
$55.0 P/Share
|
|
Jan 07
2021
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
4,000
-20.29%
|
$560,000
$140.65 P/Share
|
|
Jan 07
2021
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+16.37%
|
$84,000
$21.0 P/Share
|
|
Jan 04
2021
|
Emil D Kakkis President & CEO |
SELL
Open market or private sale
|
Indirect |
30,000
-1.27%
|
$4,080,000
$136.9 P/Share
|
|
Nov 02
2020
|
Emil D Kakkis President & CEO |
SELL
Open market or private sale
|
Indirect |
30,000
-1.26%
|
$2,880,000
$96.82 P/Share
|
|
Oct 30
2020
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,903
-29.16%
|
$990,300
$100.12 P/Share
|
|
Oct 30
2020
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,903
+22.62%
|
$534,762
$54.5 P/Share
|
|
Oct 28
2020
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
97
-0.4%
|
$9,700
$100.0 P/Share
|
|
Oct 28
2020
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
97
+0.4%
|
$5,238
$54.5 P/Share
|
|
Oct 14
2020
|
Shalini Sharp EVP, Finance |
SELL
Open market or private sale
|
Direct |
375
-0.38%
|
$32,625
$87.99 P/Share
|
|
Oct 14
2020
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
146
-0.88%
|
$12,702
$87.98 P/Share
|
|
Oct 14
2020
|
Dennis Karl Huang |
SELL
Open market or private sale
|
Direct |
262
-0.75%
|
$23,056
$88.0 P/Share
|
|
Oct 14
2020
|
John Richard Pinion |
SELL
Open market or private sale
|
Direct |
262
-0.56%
|
$23,056
$88.0 P/Share
|